27 related articles for article (PubMed ID: 38468522)
1. 3D- and 2D-QSAR models' study and molecular docking of novel nitrogen-mustard compounds for osteosarcoma.
Zhuo W; Lian Z; Bai W; Chen Y; Xia H
Front Mol Biosci; 2023; 10():1164349. PubMed ID: 37065446
[No Abstract] [Full Text] [Related]
2. QSAR Study of Novel 1, 8-Naphthimide Derivatives Targeting Nuclear DNA.
Lian Z; Tai Y; Xia H; Zhai H
Anticancer Agents Med Chem; 2023; 23(6):726-733. PubMed ID: 36017845
[TBL] [Abstract][Full Text] [Related]
3. 2D, 3D-QSAR study and docking of vascular endothelial growth factor receptor 3 (VEGFR3) inhibitors for potential treatment of retinoblastoma.
Ren R; Gao L; Li G; Wang S; Zhao Y; Wang H; Liu J
Front Pharmacol; 2023; 14():1177282. PubMed ID: 37089961
[No Abstract] [Full Text] [Related]
4. A novel non-linear approach for establishing a QSAR model of a class of 2-Phenyl-3-(pyridin-2-yl) thiazolidin-4-one derivatives.
Wu L; Chen Y; Duan K
Front Pharmacol; 2023; 14():1263933. PubMed ID: 37829302
[TBL] [Abstract][Full Text] [Related]
5. Novel quantitative structure-activity relationship model to predict activities of natural products against COVID-19.
Si Y; Xu X; Hu Y; Si H; Zhai H
Chem Biol Drug Des; 2021 Apr; 97(4):978-983. PubMed ID: 33386649
[TBL] [Abstract][Full Text] [Related]
6. Predicting the Efficacy of Novel Synthetic Compounds in the Treatment of Osteosarcoma via Anti-Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) Targets.
Zhang W; Xu S; Liu P; Li X; Yu X; Kang B
Med Chem; 2024 Mar; ():. PubMed ID: 38468522
[TBL] [Abstract][Full Text] [Related]
7. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
Hofbauer LC; Neubauer A; Heufelder AE
Cancer; 2001 Aug; 92(3):460-70. PubMed ID: 11505389
[TBL] [Abstract][Full Text] [Related]
8. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
9. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
10. Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
Mori K; Ando K; Heymann D; Rédini F
Histol Histopathol; 2009 Feb; 24(2):235-42. PubMed ID: 19085839
[TBL] [Abstract][Full Text] [Related]
11. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
Roux S; Mariette X
Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989
[TBL] [Abstract][Full Text] [Related]
12. [Progress of research on the relationship between calcitonin gene-related peptide and RANK/RANKL/OPG system in the bone reconstruction].
Wang S; Xu S; Shi Z; Wu J; Lei S; Wang Y
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2019 Apr; 33(4):511-515. PubMed ID: 30983204
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
